What's breaking now, across thousands of outlets.
BioNTech delivered a compelling piece of evidence Monday supporting the development of its CTLA-4 antibody gotistobart in lung cancer. Previously treated lung cancer patients who received the CTLA-4 antibody lived for 8.5 months longer than ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Researchers at Fox Chase Cancer Center have identified a promising approach to rebuilding tissue after skin cancer surgery that could help some patients avoid more extensive reconstructive procedures.
A new study has revealed why some people with Huntington's disease develop symptoms 10–12 years earlier and experience a more aggressive form of the disease.
Key PointsModerna's recent success in a phase 3 clinical trial for its personalized cancer vaccine was a breakthrough.
A new 3D structure of a cancer-linked protein bound to its cellular partner reveals details of how the protein binds to chromosomes and could offer insights for future disease treatments.
Researchers from the University of Liverpool and the University of Zurich have identified a potential safety consideration involving levetiracetam, one of the world's most commonly prescribed…
A Johns Hopkins Medicine study reports evidence that time-restricted eating (TRE)—a form of intermittent fasting that involves eating only during a consistent daily 8–10-hour window—can cause modest weight loss in adults with obesity and prediabetes or diet-controlled type 2 diabetes.
